Novo Nordisk (NVO) Stock Jumps as FDA Approves First Oral Weight-Loss Pill

TLDR

• Novo Nordisk’s Wegovy weight-loss pill received FDA approval on Monday, sending the stock up 9.5% in extended trading
• The once-daily oral semaglutide 25 mg pill is the first oral GLP-1 receptor agonist therapy approved for weight management in the U.S.
• Clinical trials showed participants lost an average of 16.6% of their body weight over 64 weeks compared to 2.7% on placebo
• The approval gives Novo Nordisk a head start over rival Eli Lilly, which is developing its own obesity pill called orforglipron
• Novo Nordisk plans to launch the Wegovy pill in the U.S. in early January 2026

Novo Nordisk shares surged 9.5% in Monday’s extended trading after the FDA approved the company’s Wegovy weight-loss pill. The Danish drugmaker received clearance for its once-daily oral semaglutide 25 mg tablet for chronic weight management.

Novo Nordisk A/S, NVO

The approval marks a turning point for Novo Nordisk after a rough year. The stock has dropped 44% year-to-date due to profit warnings and slowing sales of its injectable Wegovy.

The pill contains the same active ingredient as the injectable versions of Wegovy and Ozempic. Novo Nordisk already sells an oral semaglutide called Rybelsus for type 2 diabetes treatment.

This is the first oral GLP-1 receptor agonist therapy approved for weight management in the United States. The company plans to launch the pill in early January 2026.

The FDA approved the pill for adults with obesity or overweight who have at least one related health condition. This broadens the potential patient pool at a time when healthcare costs related to obesity continue to climb.

Clinical Trial Results

A 64-week late-stage study showed strong results for the oral medication. Participants taking 25 mg of oral semaglutide once daily lost an average of 16.6% of their body weight.

Those on a placebo lost just 2.7% of their body weight over the same period. The pill also received approval to reduce the risk of major cardiovascular events.

Novo Nordisk submitted the oral semaglutide 25 mg pill to the European Medicines Agency and other regulatory authorities in the second half of 2025. The company is seeking approval in multiple markets worldwide.

Competition in the Weight-Loss Market

The approval gives Novo Nordisk an edge over rival Eli Lilly in the race to bring an oral obesity medication to market. Lilly is developing its own obesity pill called orforglipron.

Lilly currently leads the weight-loss treatment market with Zepbound, its blockbuster obesity injection. Zepbound is considered more effective than Novo Nordisk’s injectable Wegovy.

The global GLP-1 market could reach $100 billion by 2030. Some forecasts project the broader weight-loss market could hit $150 billion annually by the next decade.

Compounded versions of weight-loss medications have put pressure on both companies. These lower-cost alternatives have chipped away at market share for branded treatments.

The oral pill could open access to tens of millions of patients who prefer pills over injections. Many people avoid injectable medications due to needle aversion or inconvenience.

Wall Street maintains a Moderate Buy rating on Novo Nordisk stock. The consensus is based on four Buy ratings, four Hold ratings, and one Sell rating.

Analysts set an average price target of $55.26 for the stock. This represents roughly 15% upside potential from current levels.

The company plans to launch the Wegovy pill in the U.S. in early January 2026.

The post Novo Nordisk (NVO) Stock Jumps as FDA Approves First Oral Weight-Loss Pill appeared first on CoinCentral.